Different anthracycline derivates for reducing cardiotoxicity in cancer patients
- 26 January 2004
- reference entry
- research article
- Published by Wiley
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniquesHeart, 2002
- Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patientsBritish Journal of Cancer, 2002
- Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic reviewAnnals of Oncology, 2002
- Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic reviewAnnals Of Oncology, 2002
- Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast CancerJournal of Clinical Oncology, 2001
- Anthracycline-Induced Clinical Heart Failure in a Cohort of 607 Children: Long-Term Follow-Up StudyJournal of Clinical Oncology, 2001
- Anthracycline-Induced CardiotoxicityAnnals of Internal Medicine, 1996
- New anthracycline antitumor antibioticsCritical Reviews in Oncology/Hematology, 1991
- A clinicopathologic analysis of adriamycin cardiotoxicityCancer, 1973
- CARDIAC TOXICITY OF DAUNORUBICINThe Lancet, 1969